Roy S Herbst, MD, PhD

Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Translational Working Group Leader, Thoracic Oncology Program, Yale Cancer Center

Physician Biography

Dr. Herbst is a Professor of Medicine and Pharmacology, Chief of the Medical Oncology and Associate Director for Translational Science at Yale School of Medicine and Yale Cancer Center (YCC). Prior to his appointment at Yale, Herbst was a professor of medicine, chief of the Section of Thoracic Medical Oncology, and the Barnhart Family Distinguished Professor in Targeted Therapies at MD Anderson Cancer Center. His primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients.

Dr. Herbst’s laboratory work is focused on angiogenesis and dual EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from the preclinical to clinical setting in multiple phase II and III studies which he has led. He has led the Phase I development of several of the new generation of targeted agents for NSCLC, including gefitinib, erlotinib, and bevacizumab. He co-led the BATTLE-1 effort at M.D. Anderson Cancer Center and now leads the BATTLE-2 clinical program at Yale. He serves as a Co-Program Leader of the Developmental Therapeutics Program at YCC.

Dr. Herbst is a member of the National Cancer Policy Forum for which he has organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.

After earning a B.S. and M.S. from Yale University summa cum laude, he received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from the Rockefeller University. Dr. Herbst completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Thoracic Oncology Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Board Certifications

  • Medical Oncology AB of Internal Medicine (1997)

Clinical Trials

Conditions Study Title
Lung A randomized phase II trial of combination versus single agent chemotherapy in high-risk elderly pat
Lung Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
Lung S1403
Lung PINNACLE: Phase 1b/2 Study of Anti-Notch Antibody Therapy with Cisplatin and Etoposide in SCLC
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic
Unknown Sites Novel Treatment to Enhance Smoking Cessation before Cancer Surgery
Lung A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB o
Lung Phase II Study of MEDI4736 in Locally Advanced or Metastatic NSCLC
Lung Safety and Efficacy of Abraxane Maintenance post Abraxane + Carboplatin in squamous cell lung cancer
Lung Phase I Study of DNIB0600A in NSCLC and Ovarian Cancer
Lung Biomarker-Driven Master Protocol for Squamous Cell Lung Cancer
Melanoma, skin PF-05082566 + MK-3475 IN ADVANCED SOLID TUMORS
Lung, Melanoma, skin Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets
Lung Phase 1b study of MPDL3280A with erlotinib in advanced NSCLC
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors
Bladder, Breast - Female, Lung, Pancreas, Stomach Phase 1/2 Study of Nivolumab or Nivolumab with Ipilimumab for Advanced or Metastatic Solid Tumors
Lung Phase Ib study of MEDI4736 with Tremelimumab in Advanced NSCLC
Lung Lung Cancer Mutation Consortium Protocol
Lung S1206 (8811): Ph I/II randomized Veliparib vs. placebo + Carboplatin & Paclitaxel for Stg III NSCLC
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid PCD4989g: Phase I, Open-label MPDL3280A in solid tumors

Edit this profile